Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas PDF full book. Access full book title Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas by A. T. van Oosterom. Download full books in PDF and EPUB format.
Author: A. T. van Oosterom
Publisher: Springer
ISBN:
Category : Medical
Languages : en
Pages : 536
Get Book Here
Book Description
The Boerhaave Committee for postgraduate Medical Education decided to organize a course on cancer treatment covering selected solid tumors, in which they felt important chan ges were emerging in the basic biologic, diagnostic and therapeutic concepts. Current management of cancer patients is intimately dependent on precise morphologic diagnosis, clinical staging and the proper application of all treat ment modalities. Many prominent investigators and clinicians of major can cer centers in the United States, Canada, and Europe con tributed by lecturing and during the panel discussions. This book is the tangible outcome of the productive ex changes during the meeting held December 6-8, 1979. In ovarian cancer the usefulness of histologic grading in determining prognosis has become clear. The most impor tant advance for the management of the patient is th- careful staging procedure, based on new concepts of tumor spread coupled with treatment tailored to the extent of disease. Survival appears to be directly related to the extent of the tumor mass. This has resulted in description and application of optimal cyto-reductive surgery. Radiotherapy and chemotherapy can both effectively eradi cate small amounts of tumor.
Author: A. T. van Oosterom
Publisher: Springer
ISBN:
Category : Medical
Languages : en
Pages : 536
Get Book Here
Book Description
The Boerhaave Committee for postgraduate Medical Education decided to organize a course on cancer treatment covering selected solid tumors, in which they felt important chan ges were emerging in the basic biologic, diagnostic and therapeutic concepts. Current management of cancer patients is intimately dependent on precise morphologic diagnosis, clinical staging and the proper application of all treat ment modalities. Many prominent investigators and clinicians of major can cer centers in the United States, Canada, and Europe con tributed by lecturing and during the panel discussions. This book is the tangible outcome of the productive ex changes during the meeting held December 6-8, 1979. In ovarian cancer the usefulness of histologic grading in determining prognosis has become clear. The most impor tant advance for the management of the patient is th- careful staging procedure, based on new concepts of tumor spread coupled with treatment tailored to the extent of disease. Survival appears to be directly related to the extent of the tumor mass. This has resulted in description and application of optimal cyto-reductive surgery. Radiotherapy and chemotherapy can both effectively eradi cate small amounts of tumor.
Author: A. T. van Oosterom
Publisher:
ISBN:
Category :
Languages : en
Pages : 507
Get Book Here
Book Description
Author: Allan Theo van Oosterom
Publisher:
ISBN:
Category : Ovaries
Languages : en
Pages : 536
Get Book Here
Book Description
Author: Stan Kaye
Publisher: Springer
ISBN: 9781441972156
Category : Medical
Languages : en
Pages : 291
Get Book Here
Book Description
This book offers a progress report on efforts to meet the challenges faced by ovarian cancer patients and their doctors. It provides a current perspective on therapeutic developments as a partnership between laboratory-based and clinical-based researchers.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309380499
Category : Medical
Languages : en
Pages : 397
Get Book Here
Book Description
In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.
Author: National Institutes of Health (U.S.)
Publisher:
ISBN:
Category : Biochemistry
Languages : en
Pages : 496
Get Book Here
Book Description
Each issue lists papers published during the preceding year.
Author:
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 686
Get Book Here
Book Description
Author: Robert C. Bast, Jr.
Publisher: John Wiley & Sons
ISBN: 111900084X
Category : Medical
Languages : en
Pages : 2004
Get Book Here
Book Description
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Author: Samir N. Khleif
Publisher: Lippincott Williams & Wilkins
ISBN: 1496353390
Category : Medical
Languages : en
Pages : 832
Get Book Here
Book Description
For more than 30 years, Skeel’s Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the resource of choice for current, reliable information on cancer treatment for most adults. The 9th Edition reflects recent significant advances in the systemic treatment of cancer, including innovations in immunotherapy, oncology genomics, and molecular targeted therapy. An invaluable reference for all levels of physicians, nurses, and allied health professionals who provide care to cancer patients, this bestselling guide combines the most current rationale and the details necessary to safely administer pharmacologic therapy, offering a balanced synthesis between science and clinical practice.
Author: Georges Mathe;&AAe;
Publisher: Springer Science & Business Media
ISBN: 3642816851
Category : Medical
Languages : en
Pages : 404
Get Book Here
Book Description
Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therapy. Consequently, most patients were in advanced relapse. Six of 16 recipients of syngeneic marrow and 13 of 100 recipients of allogeneic marrow are still in remission after 5. 5-10 years [3, 7]. An actuarial survival curve of the first 100 patients grafted in Seattle after conditioning with cyclophos phamide (60 mg/kg on each of 2 successive days) and total body irradiation (1,000 rad) showed three periods of interest: (1) The first 4 months showed a rapid loss of patients associated with advanced illness, graft-versus-host disease, infections (in particular interstitial pneumonias), and recurrent leukemia; (2) from 4 months to 2 years, the curve showed a much slower rate of decline attributable primarily to recurrent leukemia; and (3) from 2-10 years, the curve was almost flat with a negligible loss of patients and no recurrent leukemia. This flat portion of the curve corresponded to 13% of the patients and indicates a strong probability that the majority of these survivors are cured of their disease [8]. Attempts at reducing the incidence of leukemic relapse after transplantation were made by a number of marrow transplant groups by added chemotherapy.
